@article{JTD5595,
author = {Yuankai Shi and Yan Sun and Cuimin Ding and Ziping Wang and Changli Wang and Zheng Wang and Chong Bai and Chunxue Bai and Jifeng Feng and Xiaoqing Liu and Fang Li and Yue Yang and Yongqian Shu and Milu Wu and Jianxing He and Yiping Zhang and Shucai Zhang and Gongyan Chen and Honghe Luo and Rongcheng Luo and Caicun Zhou and Yanbin Zhou and Qingsong Pang and Hong Zhao and Qiong Zhao and Aiqin Gu and Yang Ling and Cheng Huang and Baohui Han and Shunchang Jiao and Hong Jiao},
title = {China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)},
journal = {Journal of Thoracic Disease},
volume = {7},
number = {10},
year = {2015},
keywords = {},
abstract = {According to Chinese Cancer Registry Annual Report in 2011, the incidence rate of lung cancer was 48.32/100,000 and the mortality rate was 39.27/100,000 in China in 2011, being the highest among all cancers (1). Most patients with nonsmall cell lung cancer (NSCLC) which accounts for 85% of all lung cancers have entered the advanced stage at the first visit to hospital and thus missed the opportunity for surgery. As the main treatment for advanced NSCLC, chemotherapy has reached a plateau in its efficacy and has been restricted in clinical application due to adverse reactions. In recent years, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), thanks to their definite efficacy, mild adverse reaction and convenience for oral use, have broken the bottleneck of traditional chemotherapeutic drugs and become an essential treatment for advanced NSCLC.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/5595}
}